XPC antisense RNA 1 (XPC-AS1)

**XPC antisense RNA 1 (XPC-AS1)** is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the XPC gene locus. Antisense RNAs, such as XPC-AS1, typically regulate gene expression at the epigenetic, transcriptional, or post-transcriptional level, influencing the output of specific gene loci[3][6]. XPC-AS1 is an example of antisense enhancer RNA (eRNA), which can interact with chromatin-modifying proteins and contribute to the spatial organization of enhancer and gene-ending regions. In prostate cancer cells, antisense eRNAs have been shown to recruit DNA methyltransferase DNMT1 to specific regions, facilitating DNA methylation and leading to changes in expression of neighboring mRNAs[1]. Generally, antisense RNAs play key roles in modulating gene expression, epigenetic marks, and genomic imprinting, but are not classical therapeutic targets such as receptors, enzymes, or transporters[3][6]. There is currently no evidence of clinically relevant drug interactions or direct therapeutic targeting of XPC-AS1; pharmacological strategies involving antisense RNAs usually focus on antisense oligonucleotides (ASOs) that modulate or degrade such RNAs in a sequence-specific manner[3]. No established role for XPC-AS1 as a clinical biomarker or therapeutic safety concern was found in the available literature.

Other names

XPC-AS1XPC antisense RNA 1

Not directly targeted by drugs (see "description" for function as non-coding RNA; pharmacological interest lies more in antisense oligonucleotide strategies in general[3])